-
Continued from the May 1, 2004 isssue. Part 2: Clinical Trials Summary, Recommendations, and Criteria for Use.
-
-
Pharmacists may turn to drug interaction compendia for detailed information on serious drug-drug interactions (DDIs). New research, however, shows that the compendia seldom agree on which DDIs are considered to be of the highest clinical importance. In the study, researchers found that of the 406 DDIs identified in one or more of the references as having the greatest clinical severity or importance, only nine were identified as major in all four compendia.
-
Few new antibiotics are in the pipeline; Pharmacy groups establish compounding accreditation board; Be aware of possible drug mix-ups for obstetrical patients; Pancreatic extract makers to submit marketing applications; Concurrent oxandrolone, warfarin use may have adverse effect.
-
These drugs recently received final approval from the U.S. Food and Drug Administration (FDA).
-
Midcycle self-assessments, tracer methodology, and less emphasis on examination of policy books are signs that the new survey process implemented by the Joint Commission on the Accreditation of Healthcare Organizations is truly different from the survey process of the past.
-
-
Sasser H, Barringer T. Policosanol: A natural alternative for lipid management? Altern Med Alert 2004;7(4):37-41.
-
Greenfield RH. Antibacterial soaps and infectious disease. Altern Med Alert 2004;7(4):47-48.
-
Greenfield RH. Safety of niacin. Altern Med Alert 2004;7(4):48.
